# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration...
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $178 to $139.
Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $155 to $125.
- Bloomberg
10 worst performing large-cap stocks last week: RTO, ALLY, MRNA, HUM, TSN, BEKE, ADBE, RYAAY, JPM, DVN. Consider impact on your...
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight ne...
https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997Even as the Covid wave in F...